Details for Patent: 8,178,532

Title:	c-Met modulators and method of use
Abstract:	The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
Inventor(s):	Bannen; Lynne Canne (Pacifica, CA), Chan; Diva Sze-Ming (San Francisco, CA), Forsyth; Timothy Patrick (Hayward, CA), Khoury; Richard George (Redwood City, CA), Leahy; James William (San Leandro, CA), Mac; Morrisson B. (San Francisco, CA), Mann; Larry W. (Richland, MI), Nuss; John M. (Danville, CA), Parks; Jason Jevious (Sacramento, CA), Wang; Yong (Foster City, CA), Xu; Wie (Danville, CA)
Assignee:	Exelixis, Inc. (South San Francisco, CA)
Filing Date:	May 24, 2007
Application Number:	11/753,462
Claims:	1. A compound which is represented by the following structure: ##STR00549## or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof. 3. The pharmaceutical composition of claim 2 which further includes an excipient.